ENZ Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 29 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

$3.12
As of 07/28/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  USA
Country of incorporation:  USA
IPO date:  02/15/2001
Outstanding shares:  48,471,771
Average volume:  850,460
Market cap:   $150,747,208
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    294100102
ISIN:        US2941001024
Sedol:      2318499
Valuation   (See tab for details)
PE ratio:   -392.85
PB ratio:   2.33
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy